Notably, in the Phase 1b dose escalation and expansion study of venetoclax combined with HMA in elderly patients with AML, NPM1-mutated AML was associated with a remarkably high CR + CRi [91% (138)]. Here, NPM1 is linked to acute myeloid leukemia.